Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome

E. N. Prystowsky, G. J. Klein, R. L. Rinkenberger, J. J. Heger, G. V. Naccarelli, D. P. Zipes

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

We performed electrophysiologic studies in 19 patients with accessory pathways before and during encainide therapy with a mean daily dose of 197 mg. Fourteen patients had manifest accessory atrioventricular connections, and 5 patients had concealed accessory atrioventricular connections. The patients had recurrent atrioventricular reentrant tachycardia for a mean of 15.8 years and had received a mean of 3.6 drug trials without successful suppression of recurrent arrhythmias. Encainide caused complete antegrade conduction block in the accessory pathway in 8 of 14 patients with manifest accessory atrioventricular connections. The shortest atrial pacing cycle length maintaining 1:1 conduction over the accessory pathway at control study was 328 ± 66 msec in patients in whom antegrade conduction block occurred, and it was 247 ± 21 msec (p <.01) in patients in whom conduction remained during encainide therapy. Retrograde conduction over accessory atrioventricular connections could be evaluated in 14 patients, and complete block occurred in 7 patients during encainide therapy. There was no correlation between control retrograde effective refractory period or conduction of the accessory pathway and subsequent development of conduction block with encainide therapy. It should be noted that 5 patients who developed drug-related retrograde block over the accessory pathways had initial retrograde effective refractory periods for the accessory pathway less than 270 msec. Nineteen patients had atrioventricular reentrant tachycardia initiated at control electrophysiologic study. Encainide prevented induction of tachycardia in 10 patients, and in the other 9 patients, cycle length of tachycardia increased during drug treatment from 313.9 ± 53.1 to 418.3 ± 80.9 msec (p <.001), primarily due to an increase in ventriculoatrial conduction time from 162.2 ± 43.8 to 238.3 ± 87.9 msec (p <.01). Fifteen patients continued encainide treatment for a mean of 18 months (range 7 to 38), and all but one patient remain asymptomatic. Encainide is well tolerated and prevents recurrence of reentrant tachycardia in patients with Wolff-Parkinson-White syndrome very effectively.

Original languageEnglish (US)
Pages (from-to)278-287
Number of pages10
JournalCirculation
Volume69
Issue number2
StatePublished - 1984
Externally publishedYes

Fingerprint

Encainide
Wolff-Parkinson-White Syndrome
Tachycardia
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Prystowsky, E. N., Klein, G. J., Rinkenberger, R. L., Heger, J. J., Naccarelli, G. V., & Zipes, D. P. (1984). Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. Circulation, 69(2), 278-287.

Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. / Prystowsky, E. N.; Klein, G. J.; Rinkenberger, R. L.; Heger, J. J.; Naccarelli, G. V.; Zipes, D. P.

In: Circulation, Vol. 69, No. 2, 1984, p. 278-287.

Research output: Contribution to journalArticle

Prystowsky, EN, Klein, GJ, Rinkenberger, RL, Heger, JJ, Naccarelli, GV & Zipes, DP 1984, 'Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome', Circulation, vol. 69, no. 2, pp. 278-287.
Prystowsky EN, Klein GJ, Rinkenberger RL, Heger JJ, Naccarelli GV, Zipes DP. Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. Circulation. 1984;69(2):278-287.
Prystowsky, E. N. ; Klein, G. J. ; Rinkenberger, R. L. ; Heger, J. J. ; Naccarelli, G. V. ; Zipes, D. P. / Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. In: Circulation. 1984 ; Vol. 69, No. 2. pp. 278-287.
@article{3feeb7418a674db8b5025c96562867f0,
title = "Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome",
abstract = "We performed electrophysiologic studies in 19 patients with accessory pathways before and during encainide therapy with a mean daily dose of 197 mg. Fourteen patients had manifest accessory atrioventricular connections, and 5 patients had concealed accessory atrioventricular connections. The patients had recurrent atrioventricular reentrant tachycardia for a mean of 15.8 years and had received a mean of 3.6 drug trials without successful suppression of recurrent arrhythmias. Encainide caused complete antegrade conduction block in the accessory pathway in 8 of 14 patients with manifest accessory atrioventricular connections. The shortest atrial pacing cycle length maintaining 1:1 conduction over the accessory pathway at control study was 328 ± 66 msec in patients in whom antegrade conduction block occurred, and it was 247 ± 21 msec (p <.01) in patients in whom conduction remained during encainide therapy. Retrograde conduction over accessory atrioventricular connections could be evaluated in 14 patients, and complete block occurred in 7 patients during encainide therapy. There was no correlation between control retrograde effective refractory period or conduction of the accessory pathway and subsequent development of conduction block with encainide therapy. It should be noted that 5 patients who developed drug-related retrograde block over the accessory pathways had initial retrograde effective refractory periods for the accessory pathway less than 270 msec. Nineteen patients had atrioventricular reentrant tachycardia initiated at control electrophysiologic study. Encainide prevented induction of tachycardia in 10 patients, and in the other 9 patients, cycle length of tachycardia increased during drug treatment from 313.9 ± 53.1 to 418.3 ± 80.9 msec (p <.001), primarily due to an increase in ventriculoatrial conduction time from 162.2 ± 43.8 to 238.3 ± 87.9 msec (p <.01). Fifteen patients continued encainide treatment for a mean of 18 months (range 7 to 38), and all but one patient remain asymptomatic. Encainide is well tolerated and prevents recurrence of reentrant tachycardia in patients with Wolff-Parkinson-White syndrome very effectively.",
author = "Prystowsky, {E. N.} and Klein, {G. J.} and Rinkenberger, {R. L.} and Heger, {J. J.} and Naccarelli, {G. V.} and Zipes, {D. P.}",
year = "1984",
language = "English (US)",
volume = "69",
pages = "278--287",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome

AU - Prystowsky, E. N.

AU - Klein, G. J.

AU - Rinkenberger, R. L.

AU - Heger, J. J.

AU - Naccarelli, G. V.

AU - Zipes, D. P.

PY - 1984

Y1 - 1984

N2 - We performed electrophysiologic studies in 19 patients with accessory pathways before and during encainide therapy with a mean daily dose of 197 mg. Fourteen patients had manifest accessory atrioventricular connections, and 5 patients had concealed accessory atrioventricular connections. The patients had recurrent atrioventricular reentrant tachycardia for a mean of 15.8 years and had received a mean of 3.6 drug trials without successful suppression of recurrent arrhythmias. Encainide caused complete antegrade conduction block in the accessory pathway in 8 of 14 patients with manifest accessory atrioventricular connections. The shortest atrial pacing cycle length maintaining 1:1 conduction over the accessory pathway at control study was 328 ± 66 msec in patients in whom antegrade conduction block occurred, and it was 247 ± 21 msec (p <.01) in patients in whom conduction remained during encainide therapy. Retrograde conduction over accessory atrioventricular connections could be evaluated in 14 patients, and complete block occurred in 7 patients during encainide therapy. There was no correlation between control retrograde effective refractory period or conduction of the accessory pathway and subsequent development of conduction block with encainide therapy. It should be noted that 5 patients who developed drug-related retrograde block over the accessory pathways had initial retrograde effective refractory periods for the accessory pathway less than 270 msec. Nineteen patients had atrioventricular reentrant tachycardia initiated at control electrophysiologic study. Encainide prevented induction of tachycardia in 10 patients, and in the other 9 patients, cycle length of tachycardia increased during drug treatment from 313.9 ± 53.1 to 418.3 ± 80.9 msec (p <.001), primarily due to an increase in ventriculoatrial conduction time from 162.2 ± 43.8 to 238.3 ± 87.9 msec (p <.01). Fifteen patients continued encainide treatment for a mean of 18 months (range 7 to 38), and all but one patient remain asymptomatic. Encainide is well tolerated and prevents recurrence of reentrant tachycardia in patients with Wolff-Parkinson-White syndrome very effectively.

AB - We performed electrophysiologic studies in 19 patients with accessory pathways before and during encainide therapy with a mean daily dose of 197 mg. Fourteen patients had manifest accessory atrioventricular connections, and 5 patients had concealed accessory atrioventricular connections. The patients had recurrent atrioventricular reentrant tachycardia for a mean of 15.8 years and had received a mean of 3.6 drug trials without successful suppression of recurrent arrhythmias. Encainide caused complete antegrade conduction block in the accessory pathway in 8 of 14 patients with manifest accessory atrioventricular connections. The shortest atrial pacing cycle length maintaining 1:1 conduction over the accessory pathway at control study was 328 ± 66 msec in patients in whom antegrade conduction block occurred, and it was 247 ± 21 msec (p <.01) in patients in whom conduction remained during encainide therapy. Retrograde conduction over accessory atrioventricular connections could be evaluated in 14 patients, and complete block occurred in 7 patients during encainide therapy. There was no correlation between control retrograde effective refractory period or conduction of the accessory pathway and subsequent development of conduction block with encainide therapy. It should be noted that 5 patients who developed drug-related retrograde block over the accessory pathways had initial retrograde effective refractory periods for the accessory pathway less than 270 msec. Nineteen patients had atrioventricular reentrant tachycardia initiated at control electrophysiologic study. Encainide prevented induction of tachycardia in 10 patients, and in the other 9 patients, cycle length of tachycardia increased during drug treatment from 313.9 ± 53.1 to 418.3 ± 80.9 msec (p <.001), primarily due to an increase in ventriculoatrial conduction time from 162.2 ± 43.8 to 238.3 ± 87.9 msec (p <.01). Fifteen patients continued encainide treatment for a mean of 18 months (range 7 to 38), and all but one patient remain asymptomatic. Encainide is well tolerated and prevents recurrence of reentrant tachycardia in patients with Wolff-Parkinson-White syndrome very effectively.

UR - http://www.scopus.com/inward/record.url?scp=0021341548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021341548&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 278

EP - 287

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 2

ER -